Unlocking The Promise Of Conjugate Vaccines

Espoir's Path To Affordable Protection For Infectious Diseases & Oncology.

Our mission

Espoir Therapeutics

At Espoir Therapeutics, headquartered in Canada, our mission is to make lifesaving Conjugate Vaccines accessible to all.

img-1-1-qe1be2mtycy03mraqhu43u4mn93i91ualxwg9dtkw0

GMP-Grade CRM197

Our Groundbreaking Work.

CRM197 is a vital component in bacterial conjugate vaccines such as those for Pneumococcal, Meningitis, etc.

Also for any other conjugate vaccines that require the immunogenic capacity of the CRM197 carrier, whether against viral, cancer or other diseases.

Espoir developed ESP-CRM197, offering unwavering quality and immunogenicity

Infrastructure

Strengths That Set Us Apart.

Our expertise in producing a CRM197 that exceeds the highest regulatory standards.

Our state-of-the-art laboratory in Montreal, Canada, paired with a world-class GMP manufacturing facility in Manesar, India, empowers vaccine developers to translate vaccine concepts into clinical reality.

img-3-qe1be2mtycwv6g2q2ch71mglvk73p9vxeyws7grocg
img-4-qe1be2mtycxfn1f0ef5nkqam9enaz5v40gem8famm8

Conjugate Vaccine Carrier

Our Contribution.

Espoir accelerates research and development efforts for both biosimilar and novel vaccines.

Espoir offers significant advantages to commercial vaccine developers

Affordable Vaccines

Highly competitive supply of CRM197 with CMC support for your regulatory applications

A vision to sustain affordable vaccine development.

img-2-qe1be2mtycxfn1f0ef5nkqam9enaz5v40gem8famm8

Our Team

Dany Valiquette

Chief Executive Officer

Marc Beausoleil

Chief Corporate Affairs Officer

Yacine Amrani, CPA

Chief Financial Officer

Prabuddha Kundu, Ph.D.

Managing Director

Dr. Nupur Mehrotra, MD

Chief Operating Officer

Ram Vishwakarma, Ph.D.

Scientific Advisor

Serge Moffett, Ph.D.

Director - Biology

Élodie Pastural, Ph.D. RAC

Director - Regulatory Affairs

Tze Chieh Shiao, M.Sc.

Director - Chemistry